Skip over main navigation
  • Sign up
  • Log in
  • Basket: (0 items)
The Cure Parkinson's Trust

Help us fund research to slow, stop and reverse Parkinson’s

Donate
  • Twitter
Menu
  • Home
  • Our research
    • Our mission
    • Clinical trials
    • Projects and progress
    • Research Focused Webinars
    • 3P Seminars: The Postdoc Program
    • Improving the clinical trial process
    • Apply for funding
    • Research events
    • The Tom Isaacs Award
  • About us
    • About Parkinson's
    • People with Parkinson's
    • Our story
    • Policies, partnerships & collaborations
    • Media and brand guidelines
    • Reports & accounts
    • The Trustees
  • Help us
    • Appeals
    • Give regularly
    • Major gifts
    • Challenge events
      • Running
      • Cycling
      • Trekking
      • All challenges
    • Our supporters
      • Fundraiser News
      • Fundraiser of the Year Award
      • Fundraise
        • Fundraising tips
        • Other ways to fundraise
    • Trusts & Foundations
    • Corporates
    • Legacy & In Memoriam
  • News & events
    • News
    • All events
    • Archive news
  • Get in touch
  • Shop
  • Donate
  • Administration
    • Log in
  • Basket: (0 items)

Our Mission

                                                                                                                                                                               

Since its inception in 2005, The Cure Parkinson's Trust (CPT) has challenged the view that there is no cure for Parkinson's (PD). Our mission is to find disease-modifying treatments which slow, stop or even reverse Parkinson's. Currently, management of the condition is only symptomatic. Our goal is to discover treatments that change the way the disease progresses and transform the lives of those who live with Parkinson's. Thanks to major inroads and constant advances in our understanding of PD, new efforts to match the emerging science with innovative therapies are underway around the world. Our work is to guide, promote and sustain these efforts and ultimately find a cure.

“For us, one breakthrough would be incredible, but as everyone’s Parkinson’s is different, we need multiple breakthroughs if we are to defeat Parkinson’s once and for all.”

We only fund projects that can demonstrate the potential to slow, stop, or reverse Parkinson's. Much of our drive is focused on developing new treatments that will reach people living with Parkinson’s within a five year period. Understanding how these work on a cellular basis is crucial, and we are constantly screening for potential new treatments.  

Our research committee  interrogates new proposals and analyses research reports from the trials we are funding to ensure that the science is robust, progress is effective and results are disseminated rapidly. We actively encourage collaboration between scientists and foster these relationships to accelerate progress and ultimately benefit people living with PD.

The International Linked Clinical Trials Programme

The International Linked Clinical Trials programme (iLCT), spearheaded by CPT and supported by Van Andel Research Institute (VARI), Grand Rapids, Michigan, brings together world experts in PD to review the merits of potential new ‘disease-modifying’ treatments. Often, this involves drug repurposing. Each compound reviewed has different yet compelling biochemical modes of action with the potential to slow or stop long term decline in Parkinson’s. The LCT initiative brings the most promising of these treatments immediately into clinical trials once funding is secured.



Since 2012, the iLCT committee has met annually and prioritised around 50 of these radically new approaches to be tested in people with Parkinson's in specialist neurology hospitals around the world. Read more...

Our Impact - major themes:

The first of these trials involved the repurposing of an anti-diabetic drug (Exendin-4). Certain diabetes drugs influence how individual cells work in a way that we believe is highly beneficial to ailing neurons in Parkinson's. This was completed in 2013 with promising results in terms of intercepting long term PD decline. The initial study prompted further critical questions around the possible link between insulin resistance and the development of PD. The subsequent Bydureon phase ll trial yielded further promising results. Replication is the watchword in medicine and as part of this global initiative, two new trials using similar diabetes drugs (GLP-1 agonists) are currently underway in California and France, and the Bydureon phase lll trial will begins at the end of 2019, opening up this potentially important category of drugs in treating the condition.

Find out more about our on-going repurposing programme and other clinical trials.

Further reading: Korean-based Pharma Advances Clinical Trial of SR-exenatide in Parkinson's

Restoring neuronal energy - restoring function:

Mitochondrial dysfunction: In Parkinson’s neurons, energy production and use seems to be deficient and its biochemical restoration offers huge potential for slowing down Parkinson’s progression. As two mitochondria targeted drugs under the LCT global initiative, EPI-589 and MSDC-0160 move into their PD clinical trials, we now have new uniquely sensitive ways to monitor these energy processes. We believe that, for the first time ever, it will be possible to develop personalised medicine for people with Parkinson’s, with future therapies matched to their genetics and biochemistry as much as their symptoms.

Related to this area of research, we are investigating the impact of oxidation and inflammation in the pathogenesis of Parkinson's. Ongoing trials currently focus on the potential anti-oxidant effects of several drugs. One of these is currently testing Simvastatin (a cholesterol lowering treatment) for its disease-modifying potential in PD. Trials are underway in 25 centres across England. Another promising clinical trial is investigating the disease modifying potential of an iron chelation drug to remove the build-up of excess iron from neurons, which is thought to contribute to disease progression. Previously funded basic research into drugs which might reduce oxidative stress on neurons includes calcium channel blockers.

Understanding the pathogenesis of Parkinson’s to find new treatments

How does Parkinson’s first appear and how does it impact on the body at the very earliest point? One theory holds that cell-to-cell transmission of abnormal forms of the protein alpha-synuclein help drive PD progression by a process which mirrors 'prion disease', possibly even starting in the gut neurons before migrating to the brain. An immunisation trial in Austria is currently targeting this alpha-synuclein build-up in neurons in people with PD directly. Other approaches, such as introducing a bacteriophage to disaggregate alpha-synuclein within neurons, and several drugs (such as Anle 138b) we are currently investigating also offer great promise. 

Reversing Parkinson’s through regenerative medicine

Regenerative medicine offers hope for a fundamental cure. We approved funding for the University of Edinburgh stem cell research study and the TRANSEURO Trial in Cambridge. Both trials have pioneered the groundwork for future trials using stem cells in terms of patient selection and the transplant process.

Promoting neuronal growth through delivering long-term infusions of the natural brain growth (neurotrophic) factors such as GDNF with pin-point precision into the brain is another promising line of research. The infusion delivery device has been used in a ground-breaking trial in Bristol.

To help us drive our research forward, please consider donating today - your support is crucial for our work to continue - thank you.

Click here to download our helpful infographic 'Ten Routes to a Cure' which shows the key areas of research CPT is actively pursuing.

Published: 1st May, 2018

Updated: 18th February, 2020

Author: Jessica Wright

Related topics:
  • Our Mission
Share this page
  • Email
  • Facebook
  • Twitter

Latest

  • Raid Local 2021: Ventoux Local

    Raid Local 2021: Ventoux Local

    Join us on the 16th May for Raid Local 2021: Ventoux Local. Inspired by the infamous Club des Cinglés challenge to climb Mont Ventoux using 3 different routes in one day, riders will be training, planning and mapping to cover the equivalent distance and vertical ascent of 1, 2 or all 3 of those epic routes, all in one day, all on their local roads.

  • 3P - Post Doc Seminar - 21 January

    3P - Post Doc Seminar - 21 January

    Join the 3P Seminar on Thursday 21st January (12.00 EST), as Kyla Germain, PhD Candidate in Peter Kim’s lab at The Hospital for Sick Children (University of Toronto), and Tim König, Postdoctoral Researcher in Heidi McBride’s lab at Montreal Neurological Institute (McGill University), present their research.

  • Virtual Bridge Tournament

    Virtual Bridge Tournament

    The Cure Parkinson’s Trust (CPT) supporter Pam Willis will be holding her annual bridge tournament ‘virtually’ on 25 January in support of our pioneering Parkinson’s research and would love you to join her.

  • Virtual Bridge Tournament

    Virtual Bridge Tournament

    The Cure Parkinson’s Trust (CPT) supporter Pam Willis will be holding her annual bridge tournament ‘virtually’ on 25 January 2021 in support of our pioneering Parkinson’s research and would love you to join her.

Most read

  • Breakthrough in stem cell treatment for Parkinson's

    In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.

  • Tom Isaacs

    Tom Isaacs

    We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.

  • New Evidence Suggests Parkinson's Might Not Start in The Brain

    New Evidence Suggests Parkinson's Might Not Start in The Brain

    A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut...

  • Science news

    Science news

    Read the latest Parkinson's science and research news here.

  • Trials - Repurposed Drugs

    Trials - Repurposed Drugs

    Our International Linked Clinical Trials initiative (iLCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.

  • Apply for Funding

    Apply for Funding

  • The NAC Trial - the facts

    The NAC Trial - the facts

  • Our story

    Our story

  • Diabetes Drug Potential Disease-Modifying Therapy

    Diabetes Drug Potential Disease-Modifying Therapy

    The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.

  • Alpha-synuclein and Parkinson's

    Alpha-synuclein and Parkinson's

Tag cloud

cell replacement therapy codicil Cure diabetes direct debit flowers GDNF GLP-1 Inflammation Leicestershire Country Cricket parkinsons Parkinson's placebo present Sense Park stem cells
The Science of Parkinson's - Dr Simon Stott, Deputy Director of Research

The Science of Parkinson's - Dr Simon Stott, Deputy Director of Research

Read more

Published: 2nd March, 2015

Updated: 4th August, 2020

Author: Jessica Wright

Science news

Science news

Read the latest Parkinson's science and research news here. Read more

Published: 2nd March, 2015

Updated: 1st December, 2020

Author: Jessica Wright

Related topics:
  • Projects and Progress
The Cure Collective

The Cure Collective

The Cure Collective is an opportunity to join like-minded individuals who are committed to help drive forward the quest to find a cure for Parkinson’s... Read more

Published: 3rd March, 2015

Updated: 28th July, 2020

Author: Jessica Wright

Related topics:
  • Major gifts
Parkinson's Movement

Parkinson's Movement

Read more

Published: 3rd March, 2015

Updated: 6th July, 2020

Author:

Latest tweet

  • Are you an early career scientist wondering what you can do to further your career during this time? If so, join ou… https://t.co/IEAVuHTB9R

    20thJanuary, 2021 @CureParkinsonsT
  • CPT supporter Pam Willis will be holding her annual Bridge tournament virtually, on 25 January. Take part from the… https://t.co/5yM0wMsPQK

    20thJanuary, 2021 @CureParkinsonsT
  • RT @Gavin_W_LeCol: To those that took part in the @CureParkinsonsT @GoZwift #virtual #chase with Tindall vs DROPS Le Col that would b… https://t.co/VQgcVGAZbk

    20thJanuary, 2021 @CureParkinsonsT

Facebook

Stay in touch

  • Email us
  • Twitter
  • Facebook
  • YouTube
  • LinkedIn
  • Instagram
+44 (0)20 7487 3892


SIGN UP TO RECEIVE OUR NEWSLETTERS

The Cure Parkinson’s Trust is a registered charity in England & Wales (1111816) and Scotland (SCO44368)

Terms and conditions Privacy Policy Sitemap Cookie policy Accessibility


Please note that due to current COVID restrictions and extensive home working there may be a slight delay in posting certain items from our Shop.
If you would like to discuss anything relating to a purchase, please email [email protected] – thank you for your patience. The CPT Team.